CN108619257B - 一种金莲花包衣泡腾片及其制备方法 - Google Patents
一种金莲花包衣泡腾片及其制备方法 Download PDFInfo
- Publication number
- CN108619257B CN108619257B CN201810604961.1A CN201810604961A CN108619257B CN 108619257 B CN108619257 B CN 108619257B CN 201810604961 A CN201810604961 A CN 201810604961A CN 108619257 B CN108619257 B CN 108619257B
- Authority
- CN
- China
- Prior art keywords
- layer
- trollius chinensis
- effervescent tablet
- acid
- trollius
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000007938 effervescent tablet Substances 0.000 title claims abstract description 71
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 241001312894 Trollius chinensis Species 0.000 claims abstract description 70
- 239000010410 layer Substances 0.000 claims abstract description 57
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims abstract description 26
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 25
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 24
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 17
- 239000002253 acid Substances 0.000 claims abstract description 13
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims abstract description 13
- 235000017557 sodium bicarbonate Nutrition 0.000 claims abstract description 13
- 229910000019 calcium carbonate Inorganic materials 0.000 claims abstract description 12
- 108010011485 Aspartame Proteins 0.000 claims abstract description 11
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 11
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims abstract description 11
- 239000000605 aspartame Substances 0.000 claims abstract description 11
- 235000010357 aspartame Nutrition 0.000 claims abstract description 11
- 229960003438 aspartame Drugs 0.000 claims abstract description 11
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000000811 xylitol Substances 0.000 claims abstract description 11
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 11
- 235000010447 xylitol Nutrition 0.000 claims abstract description 11
- 229960002675 xylitol Drugs 0.000 claims abstract description 11
- 239000011247 coating layer Substances 0.000 claims abstract description 7
- 229960004543 anhydrous citric acid Drugs 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims abstract description 5
- 239000011248 coating agent Substances 0.000 claims description 22
- 238000000576 coating method Methods 0.000 claims description 22
- 239000000843 powder Substances 0.000 claims description 22
- 241000612118 Samolus valerandi Species 0.000 claims description 21
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 claims description 15
- 244000247812 Amorphophallus rivieri Species 0.000 claims description 15
- 235000001206 Amorphophallus rivieri Nutrition 0.000 claims description 15
- 229920002581 Glucomannan Polymers 0.000 claims description 15
- 229920002752 Konjac Polymers 0.000 claims description 15
- 229940046240 glucomannan Drugs 0.000 claims description 15
- 239000000252 konjac Substances 0.000 claims description 15
- 235000010485 konjac Nutrition 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 238000001035 drying Methods 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 238000007873 sieving Methods 0.000 claims description 10
- 238000003825 pressing Methods 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 5
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 claims description 5
- 229940048086 sodium pyrophosphate Drugs 0.000 claims description 5
- 235000019818 tetrasodium diphosphate Nutrition 0.000 claims description 5
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 claims description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
- 241001530121 Trollius Species 0.000 claims description 4
- 229960004106 citric acid Drugs 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 238000004806 packaging method and process Methods 0.000 claims description 4
- 238000001556 precipitation Methods 0.000 claims description 4
- 239000000600 sorbitol Substances 0.000 claims description 4
- 235000010356 sorbitol Nutrition 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 235000005979 Citrus limon Nutrition 0.000 claims description 3
- 244000131522 Citrus pyriformis Species 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 3
- 239000000047 product Substances 0.000 claims description 3
- 239000002585 base Substances 0.000 abstract description 11
- 238000010521 absorption reaction Methods 0.000 abstract description 7
- 239000003513 alkali Substances 0.000 abstract description 6
- 230000007774 longterm Effects 0.000 abstract description 5
- 238000001727 in vivo Methods 0.000 abstract description 3
- 230000000052 comparative effect Effects 0.000 description 13
- 241000628997 Flos Species 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- JMSVCTWVEWCHDZ-UHFFFAOYSA-N syringic acid Chemical compound COC1=CC(C(O)=O)=CC(OC)=C1O JMSVCTWVEWCHDZ-UHFFFAOYSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000005187 foaming Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 2
- MKMCJLMBVKHUMS-UHFFFAOYSA-N Coixol Chemical compound COC1=CC=C2NC(=O)OC2=C1 MKMCJLMBVKHUMS-UHFFFAOYSA-N 0.000 description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 2
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- YIBXWXOYFGZLRU-UHFFFAOYSA-N syringic aldehyde Natural products CC12CCC(C3(CCC(=O)C(C)(C)C3CC=3)C)C=3C1(C)CCC2C1COC(C)(C)C(O)C(O)C1 YIBXWXOYFGZLRU-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 206010009152 Chronic tonsillitis Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- PLAPMLGJVGLZOV-UHFFFAOYSA-N Epi-orientin Natural products OC1C(O)C(O)C(CO)OC1C1=C(O)C=C(O)C2=C1OC(C=1C=C(O)C(O)=CC=1)=CC2=O PLAPMLGJVGLZOV-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- PTNJRKBWIYNFSY-UHFFFAOYSA-N Lirinin-O-methyl-ether Natural products COc1ccc-2c(CC3N(C)CCc4cc(OC)c(OC)c-2c34)c1 PTNJRKBWIYNFSY-UHFFFAOYSA-N 0.000 description 1
- RBVAFYCFAFADAG-UHFFFAOYSA-N Orientin Natural products OCC1OC(C(O)c2c(O)cc(O)c3C(=O)C=C(Oc23)c4ccc(O)c(O)c4)C(O)C1O RBVAFYCFAFADAG-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- JMFSHKGXVSAJFY-UHFFFAOYSA-N Saponaretin Natural products OCC(O)C1OC(Oc2c(O)cc(O)c3C(=O)C=C(Oc23)c4ccc(O)cc4)C(O)C1O JMFSHKGXVSAJFY-UHFFFAOYSA-N 0.000 description 1
- 241000208241 Tropaeolum Species 0.000 description 1
- LQSNPVIQIPKOGP-UHFFFAOYSA-N UNPD159785 Natural products OC1C(O)C(O)C(CO)OC1OC1=C(O)C=C(O)C2=C1OC(C=1C=C(O)C(O)=CC=1)=CC2=O LQSNPVIQIPKOGP-UHFFFAOYSA-N 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- MOZJVOCOKZLBQB-UHFFFAOYSA-N Vitexin Natural products OCC1OC(Oc2c(O)c(O)cc3C(=O)C=C(Oc23)c4ccc(O)cc4)C(O)C(O)C1O MOZJVOCOKZLBQB-UHFFFAOYSA-N 0.000 description 1
- 238000010669 acid-base reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 201000004484 acute conjunctivitis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 206010001093 acute tonsillitis Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000022760 infectious otitis media Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- PEFNSGRTCBGNAN-UHFFFAOYSA-N nephrocizin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C=C(C=3C=C(O)C(O)=CC=3)OC2=C1 PEFNSGRTCBGNAN-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- PLAPMLGJVGLZOV-VPRICQMDSA-N orientin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(O)C2=C1OC(C=1C=C(O)C(O)=CC=1)=CC2=O PLAPMLGJVGLZOV-VPRICQMDSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- SGEWCQFRYRRZDC-VPRICQMDSA-N vitexin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(O)C2=C1OC(C=1C=CC(O)=CC=1)=CC2=O SGEWCQFRYRRZDC-VPRICQMDSA-N 0.000 description 1
- PZKISQRTNNHUGF-UHFFFAOYSA-N vitexine Natural products OC1C(O)C(O)C(CO)OC1OC1=C(O)C=C(O)C2=C1OC(C=1C=CC(O)=CC=1)=CC2=O PZKISQRTNNHUGF-UHFFFAOYSA-N 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pulmonology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Otolaryngology (AREA)
- Ophthalmology & Optometry (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明属于中药制剂领域,具体涉及一种金莲花包衣泡腾片及其制备方法。所述金莲花包衣泡腾片依次包括包衣层、酸层、金莲花层和碱层;所述酸层主要由0.6~0.8份无水枸橼酸制成;所述金莲花层主要由0.1~0.5份金莲花提取物、0.01~0.035份阿司帕坦和0.002~0.010份木糖醇制成;所述碱层主要由0.30~0.45份碱剂制成,所述碱剂由碳酸钙和碳酸氢钠按质量比为1:(1~2)的比例组成。该金莲花包衣泡腾片将酸碱崩解剂分隔开,避免泡腾片吸湿崩解,稳定性好,能在2min内崩解完全溶解,溶解的溶液pH在4.5~6.0之间,减少长期服用泡腾片对体内酸碱平衡的影响。
Description
技术领域
本发明属于中药制剂领域,具体涉及一种金莲花包衣泡腾片及其制备方法。
背景技术
金莲花为毛茛科多年生草本植物中华金莲花的花,含有丰富的营养物质,如黄酮类成分荭草苷、牡荆苷、生物碱、树脂、软脂酸、香豆素及其苷、多糖、挥发油、鞣质、多种自醇类化合物等。金莲花以花入药,味苦、性凉,有清热解毒、抗菌消炎功能,对肺炎双球菌、绿脓杆菌、卡他球菌等有较强抑制作用;对急慢性扁桃体炎、咽炎、急性中耳炎、结膜炎及上呼吸道感染等症具有显著的治疗效果。
中国专利申请CN1559517A公开了一种更适合儿童、老人的金莲花新制剂-金莲花分散片,所述金莲花分散片由金莲花提取物、药用载体、可食用性香精和可食用性色素混合均匀制成。该发明克服了市场已有的金莲花制剂的缺点,不含糖,口感好,既可吞服,亦可用水溶服,具有服用、携带方便,不受年龄限制,适用人群广等优势,但该分散片需要在温开水中3min内才能溶解,在冷水中不能完全溶解,且崩解时间长。
泡腾剂是一种遇水可放出大量二氧化碳气体而达到快速崩解作用的新型片剂,既可以溶解于热水,又可以溶解于冷水后直接服用,具有溶解、起效迅速,携带、使用方便,生物利用度高的特点。
中国专利申请CN106420656A公开了一种金莲花泡腾片及其制备方法,所述金莲花泡腾片主要由金莲花粉、薏苡素、丁香酸、山梨醇、黄原胶、柠檬酸钠和碳酸氢钠组成。该金莲花泡腾片配方合理、科学,各组分相互协调起清热解毒、活血化瘀和消炎镇痛的功效,对特发性肺纤维化症具有显著的改善作用,可以大大的减轻特发性肺纤维化患者的痛苦。但该发明所制备的金莲花泡腾片将碱性崩解剂碳酸钠和酸性崩解剂柠檬酸、丁香酸混合在一起,吸湿后容易崩解,影响泡腾片的外观及有效性,并且所述泡腾片溶解后溶液pH<4.5,长期服用容易影响机体酸碱平衡。
因此,迫切需要一种金莲花包衣泡腾片,所述泡腾片将酸碱崩解剂分隔开,避免泡腾片吸湿崩解,同时还能具有较短的崩解时间,稳定性好,溶解的溶液pH在4.5~6.0之间,减少长期服用泡腾片对体内酸碱平衡的影响。
发明内容
本发明旨在提供一种金莲花包衣泡腾片及其制备方法,所述泡腾片将酸碱崩解剂分隔开,避免泡腾片吸湿崩解,同时还能具有较短的崩解时间,稳定性好,溶解的溶液pH在4.5~6.0之间,减少长期服用泡腾片对体内酸碱平衡的影响。
为了达到上述目的,本发明采用以下技术方案:
一种金莲花包衣泡腾片,其特征在于,所述金莲花包衣泡腾片依次包括包衣层、酸层、金莲花层和碱层;所述酸层主要由0.6~0.8份无水枸橼酸制成;所述金莲花层主要由0.1~0.5份金莲花提取物、0.01~0.035份阿司帕坦和0.002~0.010份木糖醇制成;所述碱层主要由0.30~0.45份碱剂制成,所述碱剂由碳酸钙和碳酸氢钠按质量比为1:(1~2)的比例组成。
进一步地,所述酸层主要由0.75份无水枸橼酸制成;所述金莲花层主要由0.45份金莲花提取物、0.025份阿司帕坦和0.005份木糖醇制成;所述碱层主要由0.4份碱剂制成,所述碱剂由碳酸钙和碳酸氢钠按质量比为1:1.5的比例组成。
更进一步地,所述包衣层由包衣液制成,所述包衣液主要由4~7%魔芋葡甘聚糖、0.1~0.8%山梨醇、0.1~0.5%焦磷酸钠和0.01~0.04%柠檬黄溶于75%乙醇溶液制成。
进一步地,所述金莲花提取物的提取方法包括以下步骤:
取挑拣清洗好的金莲花于提取罐内,加入金莲花重量10~15倍量的纯水,煎煮2~3次,每次1~2h,合并煎液,200目筛过滤,于55~65℃,-0.03~-0.09Mpa条件下,将煎液浓缩至常温条件下相对密度为1.10~1.15g/cm3的浓缩液,转移至酒精沉淀罐中,静置24h,取上清液300目筛过滤后用单效浓缩器于55~65℃,-0.04~-0.08Mpa的条件下将药液浓缩至常温条件下相对密度1.25~1.30g/cm3的浸膏,然后在-0.08~-0.1Mpa,55~60℃进行减压干燥,干燥物粉碎成细粉,过80目筛,得金莲花提取物。
另外的,本发明还提供了一种金莲花包衣泡腾片的制备方法,所述制备方法方法包括以下步骤:
S1、制备金莲花提取物:取挑拣清洗好的金莲花于提取罐内,加入金莲花重量10~15倍量的纯水,煎煮2~3次,每次1~2h,合并煎液,200目筛过滤,于55~65℃,-0.03~-0.09Mpa条件下,将煎液浓缩至常温条件下相对密度为1.10~1.15g/cm3的浓缩液,转移至酒精沉淀罐中,静置24h,取上清液300目筛过滤后用单效浓缩器于55~65℃,-0.04~-0.08Mpa的条件下将药液浓缩至常温条件下相对密度1.25~1.30g/cm3的浸膏,然后在-0.08~-0.1Mpa,55~60℃进行减压干燥,干燥物粉碎成细粉,过80目筛,得金莲花提取物;
S2、将无水枸橼酸低温干燥,过80目筛,作为第一层粉末备用;将步骤S1所得金莲花提取物、阿司帕坦和木糖醇按所述重量混合均匀,作为第二层粉末备用;将碳酸钙和碳酸氢钠过80目筛,作为第三层粉末备用;
S3、加入步骤S2所得第一层粉末,预压;加入步骤S2所得第二层粉末,再次预压;加入步骤S2所得第三层粉末,在控制湿度为15~30%的环境下压制,得泡腾片;
S4、将步骤S3所得泡腾片放入包衣锅内进行包衣,干燥,包装,即得。
本发明中碱层与酸层无水枸橼酸经过合理的配比,可以使碱层反应完全,酸层稍微过量,泡腾片完全溶解后,所得溶液可以保持pH在4.5~6.0之间。除此以外,本发明中间以金莲花提取物、阿司帕坦和木糖醇的混合物作为中间层将酸层与碱层分隔开,避免了酸碱层在生产贮藏过程中吸湿而发生酸碱反应,同时外加包衣防潮,提高了泡腾片的稳定性。
但分层压片会影响金莲花泡腾片的溶解性,使崩解时间延长,而申请人意外的发现,加入魔芋葡甘聚糖可使泡腾片的溶解时间显著缩短。试验证明:魔芋葡甘聚糖作为主要的包衣原料,可使泡腾片的崩解时间缩短在2min以内,加快泡腾片的溶解。但魔芋葡甘聚糖具有吸水性,作为包衣非常容易吸潮,此时加入焦磷酸钠可以提高包衣的耐水性。但同时,水分子的扩散迁移速率远远超过魔芋葡甘聚糖大分子的扩散迁移速度,容易使魔芋葡甘聚糖颗粒发生溶胀或肿胀,导致魔芋葡甘聚糖颗粒相互粘联而结块,妨碍魔芋葡甘聚糖的进一步溶解,形成絮凝状沉淀,而泡腾片产生的二氧化碳能冲散魔芋葡甘聚糖颗粒,防止其粘连结块,促进其溶解。试验证明,本发明制备的金莲花包衣泡腾片崩解时间短,在(25±2)℃,相对湿度(60±10)%的条件下放置18个月后,其性状、崩解时间、发泡量和分散均匀性基本保持不变,稳定性好。
本发明具有以下优点:
(1)本发明的金莲花包衣泡腾片采用酸碱分层压片,避免了泡腾片吸湿崩解,包衣提高泡腾片的稳定性。
(2)本发明的金莲花包衣泡腾片外观完整光洁,稳定性好,崩解时间短,可快速崩解扩散成为澄清透明溶液,具有良好的口感。
(3)本发明的金莲花包衣泡腾片酸碱剂量配比合理,可以使碱层完全反应,控制泡腾片溶解后溶液pH在4.5~6.0之间,减少长期使用泡腾片对体内酸碱平衡的影响。
附图说明
图1为金莲花包衣泡腾片结构示意图。
其中,1-包衣层,2-酸层、3-金莲花层、4-碱层。
具体实施方式
以下通过实施例形式的具体实施方式,对本发明的上述内容作进一步的详细说明。但不应将此理解为本发明上述主题的范围仅限于以下实施例。
本发明试剂均为常用试剂,可于试剂生产企业购买。
实施例1一种金莲花包衣泡腾片
一种金莲花包衣泡腾片,依次包括包衣层、酸层、金莲花层和碱层,所述酸层由0.75份无水枸橼酸制成;所述金莲花层由0.45份金莲花提取物、0.025份阿司帕坦和0.005份木糖醇制成;所述碱层由0.4份碱剂制成,所述碱剂由碳酸钙和碳酸氢钠按质量比为1:1.5的比例组成;所述包衣层由包衣液制成,所述包衣液主要由6%魔芋葡甘聚糖、0.3%山梨醇、0.5%焦磷酸钠和0.03%柠檬黄溶于75%乙醇溶液制成。
制备步骤:
S1、制备金莲花提取物:取挑拣清洗好的金莲花于提取罐内,加入金莲花重量15倍量的纯水,煎煮3次,每次1.5h,合并煎液,200目筛过滤,于60℃,-0.07Mpa条件下,将煎液浓缩至常温条件下相对密度为1.13g/cm3的浓缩液,转移至酒精沉淀罐中,静置24h,取上清液300目筛过滤后用单效浓缩器于60℃,-0.07Mpa的条件下将药液浓缩至常温条件下相对密度1.26g/cm3的浸膏,然后在-0.01Mpa,60℃进行减压干燥,干燥物粉碎成细粉,过80目筛,得金莲花提取物;
S2、将无水枸橼酸低温干燥,过80目筛,作为第一层粉末备用;将步骤S1所得金莲花提取物、阿司帕坦和木糖醇按所述重量混合均匀,作为第二层粉末备用;将碳酸钙和碳酸氢钠过80目筛,作为第三层粉末备用;
S3、加入步骤S2所得第一层粉末,预压;加入步骤S2所得第二层粉末,再次预压;加入步骤S2所得第三层粉末,在控制湿度为15~30%的环境下压制,得泡腾片;
S4、将步骤S3所得泡腾片放入包衣锅内进行包衣,干燥,包装,即得。
实施例2一种金莲花包衣泡腾片
实施例2与实施例1的区别在于,碳酸钙和碳酸氢钠的质量比为1:2,其余参数及操作参考实施例1。
实施例3一种金莲花包衣泡腾片
实施例3与实施例1的区别在于,碳酸钙和碳酸氢钠的质量比为1:1,其余参数及操作参考实施例1。
对比例1一种金莲花包衣泡腾片
对比例1与实施例1的区别在于,进行混合压片,制备方法包括以下步骤:
S1、参考实施例1提取金莲花,得金莲花提取物;
S2、取金莲花提取物、低温干燥后过80目筛的无水枸橼酸、阿司帕坦和木糖醇按所述重量份数混合均匀,再加入过80目筛的碳酸钙和碳酸氢钠,在控制湿度为25%的环境下混合均匀,进行压片,得泡腾片,将所得泡腾片放入包衣锅内进行包衣,干燥,包装,即得。
其余参数及操作参考实施例1。
对比例2一种金莲花包衣泡腾片
对比例2与实施例1的区别在于,对比例2的包衣不添加焦磷酸钠,其余参数及操作参考实施例1。
对比例3一种金莲花包衣泡腾片
对比例3与实施例1的区别在于,对比例3的包衣将魔芋葡甘聚糖替换为等量的羟甲基纤维素。
试验例1金莲花包衣泡腾片稳定性试验
1.试验材料:实施例1~3和对比例1~3制备的金莲花包衣泡腾片。
2.试验方法:在(25±2)℃,相对湿度(60±10)%的条件下放置18个月,于0、3、6、12、18个月取样,参考《中国药典》2015年版第四部附录片剂的方法,考察实施例1和对比例1~3制备的金莲花包衣泡腾片的性状、崩解时间、发泡量和分散均匀性。
3.试验结果:试验结果参见表1。
表1金莲花包衣泡腾片的稳定性试验
由表1可知,本发明实施例1~3在0~18个月的稳定性试验中性状、崩解时间、发泡量和分散均匀性基本无差异,稳定性好。对比例1(混合压片)和对比例2(无焦磷酸钠)分别在第12和第6个月吸湿造成泡腾片表面失光,凹凸不平,崩解时间显著缩短,溶液变浑浊。对比例3(魔芋葡甘聚糖替换为羟甲基纤维素)在第0个月崩解时间就显著延长,第18个月的崩解时间还大于2min。
上述实施例仅例示性说明本发明的原理及其功效,而非用于限制本发明。任何熟悉此技术的人士皆可在不违背本发明的精神及范畴下,对上述实施例进行修饰或改变。因此,举凡所属技术领域中具有通常知识者在未脱离本发明所揭示的精神与技术思想下所完成的一切等效修饰或改变,仍应由本发明的权利要求所涵盖。
Claims (2)
1.一种金莲花包衣泡腾片,其特征在于,所述金莲花包衣泡腾片酸层由0.6~0.8份无水枸橼酸制成;金莲花层由0.1~0.5份金莲花提取物、0.01~0.035份阿司帕坦和0.002~0.010份木糖醇制成;碱层由0.30~0.45份碱剂制成,所述碱剂由碳酸钙和碳酸氢钠按质量比为1:(1~2)的比例组成;
包衣层由包衣液制成,所述包衣液由4~7%魔芋葡甘聚糖、0.1~0.8%山梨醇、0.1~0.5%焦磷酸钠和0.01~0.04%柠檬黄溶于75%乙醇溶液制成;
所述金莲花包衣泡腾片的制备方法方法包括以下步骤:
S1、制备金莲花提取物:取挑拣清洗好的金莲花于提取罐内,加入金莲花重量10~15倍量的纯水,煎煮2~3次,每次1~2h,合并煎液,200目筛过滤,于55~65℃,-0.03~-0.09Mpa条件下,将煎液浓缩至常温条件下相对密度为1.10~1.15g/cm3的浓缩液,转移至酒精沉淀罐中,静置24h,取上清液300目筛过滤后用单效浓缩器于55~65℃,-0.04~-0.08Mpa的条件下将药液浓缩至常温条件下相对密度1.25~1.30g/cm3的浸膏,然后在-0.08~-0.1Mpa,55~60℃进行减压干燥,干燥物粉碎成细粉,过80目筛,得金莲花提取物;
S2、将无水枸橼酸低温干燥,过80目筛,作为第一层粉末备用;将步骤S1所得金莲花提取物、阿司帕坦和木糖醇按所述重量混合均匀,作为第二层粉末备用;将碳酸钙和碳酸氢钠过80目筛,作为第三层粉末备用;
S3、加入步骤S2所得第一层粉末,预压;加入步骤S2所得第二层粉末,再次预压;加入步骤S2所得第三层粉末,在控制湿度为15~30%的环境下压制,得泡腾片;
S4、将步骤S3所得泡腾片放入包衣锅内进行包衣,干燥,包装,即得。
2.如权利要求1所述金莲花包衣泡腾片,其特征在于,所述酸层由0.75份无水枸橼酸制成;所述金莲花层由0.45份金莲花提取物、0.025份阿司帕坦和0.005份木糖醇制成;所述碱层由0.4份碱剂制成,所述碱剂由碳酸钙和碳酸氢钠按质量比为1:1.5的比例组成。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810604961.1A CN108619257B (zh) | 2018-06-13 | 2018-06-13 | 一种金莲花包衣泡腾片及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810604961.1A CN108619257B (zh) | 2018-06-13 | 2018-06-13 | 一种金莲花包衣泡腾片及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108619257A CN108619257A (zh) | 2018-10-09 |
CN108619257B true CN108619257B (zh) | 2021-08-06 |
Family
ID=63691574
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810604961.1A Active CN108619257B (zh) | 2018-06-13 | 2018-06-13 | 一种金莲花包衣泡腾片及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108619257B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111265417B (zh) * | 2020-02-12 | 2023-02-24 | 东莞市星泽日用品有限公司 | 一种防潮包覆浴盐球及其制备方法 |
CN113350300B (zh) * | 2021-05-06 | 2022-12-02 | 广东药科大学 | 一种3d打印中药泡腾片及其制备方法 |
CN114680209B (zh) * | 2022-04-22 | 2024-06-21 | 杭州茗宝生物科技有限公司 | 一种冷泡果茶及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1733094A (zh) * | 2005-09-07 | 2006-02-15 | 北京因科瑞斯生物制品研究所 | 一种金莲花泡腾片及其制备方法 |
CN1742823A (zh) * | 2005-08-08 | 2006-03-08 | 李佳旺 | 金莲花含化片配制方法及其适应症 |
-
2018
- 2018-06-13 CN CN201810604961.1A patent/CN108619257B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1742823A (zh) * | 2005-08-08 | 2006-03-08 | 李佳旺 | 金莲花含化片配制方法及其适应症 |
CN1733094A (zh) * | 2005-09-07 | 2006-02-15 | 北京因科瑞斯生物制品研究所 | 一种金莲花泡腾片及其制备方法 |
Non-Patent Citations (3)
Title |
---|
三氯异氰尿酸泡腾片的制备和评价;禹朝华;《中国优秀硕士学位论文全文数据库(电子期刊)•医药卫生科技辑》;20160630;E079-34,第8-9页 * |
妇安泡腾片薄膜衣材料的选择及工艺研究;周瑾等;《中国药业》;20010725(第07期);第52-53页 * |
金莲花提取工艺研究;张怡等;《黑龙江医药》;20031231(第04期);第276-278页 * |
Also Published As
Publication number | Publication date |
---|---|
CN108619257A (zh) | 2018-10-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108619257B (zh) | 一种金莲花包衣泡腾片及其制备方法 | |
CN106562438A (zh) | 一种增强免疫力的组合物及其制备方法 | |
CN106420484A (zh) | 一种安肌舒敏精华液 | |
CN106668144B (zh) | 一种中草药降压茶及其制备方法 | |
CN100542584C (zh) | 复方沙棘含片及其制备方法 | |
CN103223111B (zh) | 一种治疗糖尿病肾病的中药组合物及其制备方法 | |
CN101007071A (zh) | 治疗急、慢性肠、胃炎及细菌性痢疾的中药及其制备工艺 | |
CN102894364B (zh) | 一种苦瓜绿茶降糖含片的制备方法 | |
CN114984098B (zh) | 一种山楂鸡内金咀嚼片及其制备方法 | |
CN107625852A (zh) | 一种清热利湿化瘀止带中药组合物及其制备工艺和应用 | |
CN101732555A (zh) | 一种治疗感冒咳嗽及慢性支气管炎的药 | |
CN103690811A (zh) | 一种降血压、预防头昏眼花的中药口服液及其制备方法 | |
CN101491628B (zh) | 一种杞菊地黄制剂的制备方法 | |
CN114304465A (zh) | 一种橄榄叶提取物泡腾片及制作方法 | |
CN104147080A (zh) | 中药制剂、制备方法及其应用 | |
CN105582335A (zh) | 一种石斛保健品 | |
CN110916036A (zh) | 一种佐酒露及其制备方法 | |
CN100500138C (zh) | 一种消癌平制剂及其制备方法 | |
CN104547494A (zh) | 治疗甲亢的中药组合物药酒及制备工艺 | |
CN105343723A (zh) | 一种桔远止咳微囊的制备方法 | |
CN100571769C (zh) | 扎木萨-4味的颗粒剂及其制备方法 | |
CN110075193A (zh) | 复方五色梅植物提取物及其制备方法和应用 | |
CN105287931A (zh) | 一种复方银花抗感分散片及其制备方法 | |
CN107582954B (zh) | 一种珍黄胃片及其制备方法 | |
CN1660332A (zh) | 双黄连滴心丸制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |